Daniel Cloutier - Brain Scientific Chief Director
| BRSF Stock | USD 0.75 0.00 0.00% |
Insider
Daniel Cloutier is Chief Director of Brain Scientific
| Age | 57 |
| Phone | 917-388-1578 |
| Web | https://www.brainscientific.com |
Brain Scientific Management Efficiency
The company has return on total asset (ROA) of (1.1699) % which means that it has lost $1.1699 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (45.9733) %, meaning that it created substantial loss on money invested by shareholders. Brain Scientific's management efficiency ratios could be used to measure how well Brain Scientific manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Charles III | Anika Therapeutics | N/A | |
| Ronen CPA | Icecure Medical | 55 | |
| Niclas Emanuelsson | BICO Group AB | 52 | |
| Chi Nguyen | Neuropace | 47 | |
| Aron Tendler | BrainsWay | N/A | |
| Trent Northcutt | Aurora Spine | 56 | |
| Naum Muchnik | Icecure Medical | 48 | |
| Stephen Denaro | Anteris Technologies | N/A | |
| Mikael Engblom | BICO Group AB | 46 | |
| Artur Aira | BICO Group AB | 56 | |
| Anne Nunes | Anika Therapeutics | 54 | |
| Laszlo Garamszegi | Aurora Spine | 52 | |
| Jason Clifton | Cellink AB | N/A | |
| Michael Goodman | STRATA Skin Sciences | N/A | |
| Keith Simeone | STRATA Skin Sciences | N/A | |
| Karin Danielsson | Cellink AB | 41 | |
| Richard Areglado | BrainsWay | 59 | |
| Rebecca Kuhn | Neuropace | 63 | |
| William MBA | STRATA Skin Sciences | 58 | |
| Mark Saxton | Neuropace | 59 | |
| Martha Morrell | Neuropace | 67 | |
Management Performance
| Return On Equity | -45.97 | |||
| Return On Asset | -1.17 |
Brain Scientific Leadership Team
Elected by the shareholders, the Brain Scientific's board of directors comprises two types of representatives: Brain Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brain. The board's role is to monitor Brain Scientific's management team and ensure that shareholders' interests are well served. Brain Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brain Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hassan Kotob, CEO Chairman | ||
| Irina Nazarova, Director Marketing | ||
| Farid Anthony, Chief Officer | ||
| Daniel Cloutier, Chief Director | ||
| Kevin Winterfield, VP Communications | ||
| BonnieJeanne Gerety, Chief Officer | ||
| Vadim Sakharov, Consultant | ||
| Mark Broderick, Pres Corp | ||
| Stuart Bernstein, VP Marketing |
Brain Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Brain Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -45.97 | |||
| Return On Asset | -1.17 | |||
| Operating Margin | (28.77) % | |||
| Current Valuation | 12.28 M | |||
| Shares Outstanding | 105.4 M | |||
| Shares Owned By Insiders | 23.83 % | |||
| Shares Owned By Institutions | 18.54 % | |||
| Price To Sales | 26.56 X | |||
| Revenue | 265.75 K | |||
| Gross Profit | 83.23 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Brain Pink Sheet
Brain Scientific financial ratios help investors to determine whether Brain Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Brain with respect to the benefits of owning Brain Scientific security.